论文部分内容阅读
最近,组织蛋白酶B 与恶性肿瘤侵袭、转移的联系已引人注目。有人报道肝细胞癌(HCC)病人血清组织蛋白酶B 活性升高,作者用N-苄氧羰基-L—精氨酰基-L-精氨酸-7-(4-甲基)—香豆酰胺(Z-Arg-Arg-NMec)检测得的血清组织蛋白酶B 活性却不是这样,认为血清中有该酶抑制物的存在。因此,作者研究了HCC 等各种肝病人血清中组织蛋白酶B 抑制物的性状及其动态变化,将所得结果报道于此。方法:(1)按Mort 等所用的方法使大鼠肝组织匀浆(1∶5)的组织蛋白酶B 等电聚焦电泳,观察人血清添加后对活性染色带的影响。并且,用
Recently, the association between cathepsin B and the invasion and metastasis of malignant tumors has drawn attention. It has been reported that serum cathepsin B activity is elevated in patients with hepatocellular carcinoma (HCC). The authors used N-benzyloxycarbonyl-L-arginyl-L-arginine-7-(4-methyl)-coumarylamide ( This was not the case for serum cathepsin B activity detected by Z-Arg-Arg-NMec), and it is believed that there is an enzyme inhibitor present in the serum. Therefore, the authors studied the traits and dynamic changes of cathepsin B inhibitors in serum of various liver patients such as HCC, and reported the results here. METHODS: (1) The cathepsin B isoelectric (1:5) isoelectric focusing electrophoresis of rat liver was performed according to the method used by Mort et al. to observe the effect of human serum on the activity of the band. And, with